Magenta Therapeutics to Present Clinical Results and Preclinical Research at of ASH Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, a biotechnology company developing therapeutics to improve and expand the use of curative bone marrow transplant for more patients, today announced that the Company will present clinical data from its stem cell expansion program and insights into its preclinical research at the 59^th annual meeting of the American Society of Hematology (ASH), taking place December 9^th through 12^th in Atlanta, Ga.

“Magenta Therapeutics is developing new, transformative drugs to extend the curative potential of bone marrow transplant and cell therapies to more patients. We are excited to present data at ASH this year that highlight our stem cell expansion and mobilization programs, as well as a subset of our antibody-based bone marrow transplant conditioning programs,” said Michael Cooke, Ph.D., chief scientific officer, Magenta Therapeutics. “We are also looking forward to the presentation of clinical data from our most advanced program in stem cell expansion, MGTA-456, which has previously delivered promising results in a Phase 2 study.”

Oral Presentations:

Phase 2 Trials with MGTA-456, Single Cord Blood Units (CBU) Expanded with an Aryl Hydrocarbon Receptor (AHR) Antagonist, Demonstrate Uniform Engraftment and Rapid Hematopoietic Recovery in Patients Following Myeloablative or Non-Myeloablative Conditioning (Abstract #662)
Presenter: John Wagner, M.D., Director, Blood and Marrow Transplantation Division, University of Minnesota
Session Name: 721 Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Alternative Donor Transplants
Session Date: Monday, December 11, 2017
Session Time: 10:30 AM - 12:00 PM
Presentation Time: 10:45 AM
Room: Georgia World Congress Center, Building C, Level 2, C202-204

Phenotype Does Not Always Equal Function: HDAC Inhibitors and UM171, But Not SR1, Lead to Rapid Upregulation of CD90 on Non-Engrafting CD34+CD90-Negative Human Cells (Abstract #659)
Presenter: Kevin Goncalves, Ph.D., scientist, Magenta Therapeutics
Session Name: 711. Cell Collection and Processing: Optimization of Hematopoietic Graft Using Small Molecules in Culture
Session Date: Monday, December 11, 2017
Session Time: 10:30 AM - 12:00 PM
Presentation Time: 11:30 AM
Room: Georgia World Congress Center, Building B, Level 2, B216-B217

Poster Presentations:

Non-Genotoxic Conditioning for Hematopoietic Stem Cell Transplant Using a Human Antibody Drug Conjugate Targeting C-KIT (Abstract #1894)
Presenter: Adam Hartigan, Ph.D., senior scientist, Magenta Therapeutics
Session Name: 701. Experimental Transplantation: Basic Biology, Pre-Clinical Models: Poster I
Date: Saturday, December 9, 2017
Presentation Time: 5:30 PM - 7:30 PM
Location: Georgia World Congress Center, Building A, Level 1, Hall A2

The Combination of GROb and AMD3100 leads to Rapid and Robust Mobilization of Hematopoietic Stem Cells in Nonhuman Primates (Abstract #1920)
Presenter: Patrick Falahee, Ph.D., scientist, Magenta Therapeutics
Session Name: 711. Cell Collection and Processing: Poster I
Date: Saturday, December 9, 2017
Presentation Time: 5:30 PM - 7:30 PM
Location: Georgia World Congress Center, Building A, Level 1, Hall A2

Aryl Hydrocarbon Receptor Antagonists Expand Adult Hematopoietic Stem Cells from Mobilized Peripheral Blood and Bone Marrow and Increase the Dose of CRISPR/Cas9 Gene-Edited NSG-Repopulating Cells (Abstract #3341)
Presenter: Megan Hoban, Ph.D., scientist, Magenta Therapeutics
Session Name: 801. Gene Therapy and Transfer: Poster II
Date: Sunday, December 10, 2017
Presentation Time: 6:00 PM - 8:00 PM
Location: Georgia World Congress Center, Building A, Level 1, Hall A2

About Magenta Therapeutics

Magenta Therapeutics is a biotechnology company developing therapeutics to revolutionize stem cell transplantation for patients with immune and blood-based diseases. By creating a platform focused on critical areas of transplant medicine, Magenta Therapeutics is pioneering an integrated approach to stem cell therapies to change patients’ lives. Founded by internationally recognized leaders in stem cell transplant medicine, Magenta Therapeutics was launched in 2016 by Third Rock Ventures and Atlas Venture and is headquartered in Cambridge, Mass. For more information, please visit www.magentatx.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171101006000/en/